Drug Profile
Research programme: cancer immunotherapy - PrimeVax Immuno-Oncology
Alternative Names: PV-001; PV-001-DCLatest Information Update: 29 Nov 2022
Price :
$50
*
At a glance
- Originator Centers for Disease Control and Prevention; PrimeVax Immuno-Oncology
- Developer PrimeVax Immuno-Oncology
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 29 Nov 2022 Preclinical development is ongoing for Cancer in USA (NCT03990493)
- 08 Aug 2022 PrimeVax Immuno-Oncology plans a phase I trial for Malignant melanoma (Second-line therapyor greater, Inoperable/unresectable, Late-stage disease, Metastatic disease, Combination therapy) in USA (Intratumoural, Injection), in April 2023 (NCT03989895)
- 08 Aug 2022 PrimeVax Immuno-oncology plans a phase I trial for Malignant melanoma (Metastatic disease, Second-line therapy or greater) in USA (IV) in April 2023 (NCT03803397)